Guest guest Posted September 19, 2010 Report Share Posted September 19, 2010 I'm very curious why the dosage of this comparison has been changed from the 2000mg of ofatumumab for 8 weeks (well, 7 really, the first is only 300) and then every month for 4 months which adds up to quite a bit more of O than in the clinical trial. I've been on O for the 8 weeks and next week will start the monthly for 4 weeks but I have serious side effects of neuropathy and extreme fatigue. I called Glaxo and they said no side effect in trial of PN. Of course the fatigue is one of the first symptoms. But could the extremeness of the fatigue be because the dose is so high? I then called the FDA because Glaxco said they didn't have follow-up side effects after the trial was over. I think that is probably not true, but couldn " t get any info from them and they said to try the FDA. FDA of course never called me back. I'm extremely concerned about continuing the O treatments because of the neuropathy. Will it go away or will it not? If I stop now will this help it to go away or at least not progress. No one knows. I had an email from one person who also had PN but my doctor cannot understand why a CD-20 targeting agent could cause PN. so i'm left with not knowing what to do. I think these trials and follow-ups really can be very sloppy with side effects. If my doctor refuses to believe this is an O side effect and then does not report it, it will obviously not appear anywhere as a side effect and then he will have more reason to not believe it is one. I seriously think that side effects need to be taken more seriously, lots of seriously here! For those of us going through them, we need to know what happens down the road. Where is the followup? Carol Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.